MARKET

AEMD

AEMD

Aethlon Medical
NASDAQ
0.3580
-0.0087
-2.37%
Pre Market: 0.3580 0 0.00% 08:08 04/01 EDT
OPEN
0.3600
PREV CLOSE
0.3667
HIGH
0.3849
LOW
0.3510
VOLUME
37
TURNOVER
--
52 WEEK HIGH
1.790
52 WEEK LOW
0.2375
MARKET CAP
7.40M
P/E (TTM)
-0.2449
1D
5D
1M
3M
1Y
5Y
1D
Weekly Report: what happened at AEMD last week (0324-0328)?
Weekly Report · 1d ago
Weekly Report: what happened at AEMD last week (0317-0321)?
Weekly Report · 03/24 11:18
Weekly Report: what happened at AEMD last week (0310-0314)?
Weekly Report · 03/17 11:29
Aethlon Medical Price Target Maintained With a $7.00/Share by HC Wainwright & Co.
Dow Jones · 03/10 17:17
HC Wainwright & Co. Reiterates Buy on Aethlon Medical, Maintains $7 Price Target
Benzinga · 03/10 17:07
Buy Rating for Aethlon Medical Driven by Hemopurifier’s Potential in Organ Transplantation and Projected Growth
TipRanks · 03/10 14:55
Aethlon Medical Publishes Preclinical Data On The Hemopurifier In Transplant Immunology Journal Entitled, " A Lectin Affinity Plasmapheresis Device Removes Extracellular Vesicles And MicroRNAs From Renal Perfusates Following Controlled Oxygenated Rewarming Of Discarded Donor Kidneys."
Benzinga · 03/10 12:07
Weekly Report: what happened at AEMD last week (0303-0307)?
Weekly Report · 03/10 11:31
More
About AEMD
More
Aethlon Medical, Inc. is a medical therapeutic company focused on developing the Hemopurifier, a clinical-stage immunotherapeutic device which is designed to combat cancer and life-threatening viral infections and for use in organ transplantation. The Hemopurifier, in pre-clinical studies, has demonstrated the removal of harmful exosomes from biological fluids, utilizing its lectin-based technology. The Hemopurifier is a United States Food and Drug Administration (FDA) designated Breakthrough Device indicated for the treatment of individuals with advanced or metastatic cancer who are either unresponsive to or intolerant of standard of care therapy, and with cancer types in which exosomes have been shown to participate in the development or severity of the disease. The Hemopurifier also holds an FDA Breakthrough Device designation and an open Investigational Device Exemption application related to the treatment of life-threatening viruses that are not addressed with approved therapies.
Recently
Symbol
Price
%Change

Webull offers Aethlon Medical Inc stock information, including NASDAQ: AEMD real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, AEMD stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading AEMD stock methods without spending real money on the virtual paper trading platform.